30 results about "Chronic stage" patented technology

The present inventors assessed the effect of anti-IL-6 receptor antibodies in suppressing chronic rejection reaction. They assessed the effect of anti-mouse IL-6 receptor antibody (MR16-1) administration in suppressing the chronic rejection reaction using a mouse model for post-heart-transplantation chronic rejection. The result of histopathological analysis of transplanted hearts extirpated 60 days after transplantation revealed that fibrosis of myocardium and vascular stenotic lesions, which are pathological conditions characteristic of the chronic rejection reaction, were significantly suppressed in the MR16-1-treated group as compared to the control group. Thus, MR16-1 administration was demonstrated to have the effect of suppressing chronic rejection reaction. Specifically, the present inventors discovered for the first time that the rejection reaction in the chronic phase after organ transplantation was suppressed by administering an anti-IL-6 receptor antibody.

It is intended to provide a drug which is efficacious in treating and preventing diseases wherein ischemia or an inflammatory substance associated with ischemia participates in the onset or worsening thereof. Because of containing as the active ingredient a substance selected from among farnesol, a farnesol derivative, a tocopherol derivative, a tocotrienol derivative, pharmacologically acceptable salts thereof and solvates thereof, the above-described inhibitor of ischemic disorders can exert therapeutic and preventive effects on diseases wherein ischemia or an inflammatory substance associated with ischemia participates in the onset or worsening thereof (for example, brain infarction, brain edema, cardiac infarction, etc.) not only by the administration in the acute ischemic stage but also by the therapeutic administration in subacute and / or chronic stages after ischemia-reperfusion. It is also intended to provide a farnesol carboxylic acid ester derivative and a method of producing the same.

The compound Chinese onion preparation for treating chronic obstructive lung disease is prepared with Chinese onion, trichosanthes peel, Chinese goldthread, immature bitter orange, cassia twig and other chinese medicine materials. The preparation process includes crushing material, ethanol extraction, depression recovery of ethanol, concentration, adding supplementary material, vacuum drying to obtain dry extract, crushing, and further steps to prepare tablet, capsule, drip pills and micro pills. The compound Chinese onion preparation has obvious functions of relieving cough, eliminating phlegm and relieving asthma, and may be used to treat chronic obstructive lung disease effectively. It is ideal medicine for COPD in acute stage and COPD in prolonged stage and chronic stage.

The invention discloses application of a matching medicament to the preparation of medicaments for treating chronic gout with gouty tophus. The medicament consists of concentrated kidney tonifying and rheumatism eliminating pills and gout granules. The matching medicament has a reasonable formula and a good treatment effect.

The invention relates to reparation of 5-chloro-3-(4-methylsulfonyl) phenyl-2-(2-methyl-5-pyridyl) pyridine which is a high-selectivity cycloxygenase-2(COX-2) inhibitor, has the functions of preventing inflammation, clearing heat, relieving pain and the like, has a very good curative effect on signs and symptoms of osteoarthritis in the acute stage and the chronic stage and on the acute gouty arthritis, and is an important non-steride anti-inflammatory medicine. According to the method, the medicine is prepped by virtue of three steps as shown in the specification by taking 4-methylsulfonyl phenylacetic acid as a raw material.

It is intended to provide a drug which is efficacious in treating and preventing diseases wherein ischemia or an inflammatory substance associated with ischemia participates in the onset or worsening thereof. Because of containing as the active ingredient a substance selected from among farnesol, a farnesol derivative, a tocopherol derivative, a tocotrienol derivative, pharmacologically acceptable salts thereof and solvates thereof, the above-described inhibitor of ischemic disorders can exert therapeutic and preventive effects on diseases wherein ischemia or an inflammatory substance associated with ischemia participates in the onset or worsening thereof (for example, brain infarction, brain edema, cardiac infarction, etc.) not only by the administration in the acute ischemic stage but also by the therapeutic administration in subacute and / or chronic stages after ischemia-reperfusion. It is also intended to provide a farnesol carboxylic acid ester derivative and a method of producing the same.

This relates to an agent or method for treating severe aphasia in cerebrovascular accident chronic stage, which comprises 2-oxo-1-pyrrolidineacetamide as an active ingredient.

The invention particularly relates to a compound pumpkin vine ointment and a preparation method thereof. Every 1000 parts by weight of ointment comprises the following active pharmaceutical ingredients in parts by weight: 51.73-71.73 parts of pumpkin vine (carbonized), 39.38-49.38 parts of mirabilite, 2.35-22.35 parts of Chinaberry seed (carbonized), 10.58-30.58 parts of phenol, 155.76-255.76 parts of flour, and the balance of water and caramel. The preparation method comprises the following steps: adding mirabilite into a certain amount of water, heating to dissolve the mirabilite, filtering, and collecting the filtrate; adding pumpkin vine (carbonized) and Chinaberry seed (carbonized) which are pulverized into fine powder and screened, evenly mixing, adding a right amount of caramel, evenly mixing, and adding flour while evenly stirring; and finally, adding phenol, and evenly mixing to obtain the compound pumpkin vine ointment. The compound pumpkin vine ointment has comprehensive and unique effects on diminishing inflammations, removing toxicity, promoting the subsidence of swelling, alleviating pain, evacuating pus, promoting blood circulation and dredging collaterals for ulcerand furuncle, and can be effectively used in acute and chronic stages of ulcer as well as early, medium and later stages of ulcer. The compound pumpkin vine ointment can quickly take effect, and is not irritating to skin.

Myelodysplastic syndrome (MDS) is a clonal disorder of hematopoietic stem cells (HSC). Clinical course of MDS can be divided into several stages; an indolent chronic phase termed “refractory anemia (RA)” or “RA with ringed sideroblasts”, and advanced stages including “RA with excess of blasts (RAEB)” and MDS-associated leukemia. Despite a relatively high incidence of MDS, there are few effective means to treat individuals at its advanced stages. DNA microarray would be a useful tool to clarify the molecular pathogenesis of, and to develop novel treatments against, MDS. However, a simple comparison with DNA microarray of bone marrow (BM) mononuclear cells from individuals at distinct stages of MDS would mainly lead to the identification of “pseudo-positive” genes whose expression alterations only reflect the difference in the proportion of MDS blasts within BM. To efficiently analyze the stage-progression mechanism in MDS, AC133 cell surface marker-positive HSC was purified from BM of healthy volunteers as well as 30 MDS patients, and used to compare the expression profiles of 2304 genes by microarray made by the inventor. The inventor succeeded in isolating sets of genes, expression of which was specific to either indolent stage or the advanced ones.

The invention discloses Babesia mocroti antigen proteins 2D33 and 2D36 and application of the Babesia mocroti antigen proteins. The amino acid sequences of the Babesia mocroti antigen proteins are respectively represented by SEQ ID NO:4 or SEQ ID NO:6, and an encoding gene sequence of Babesia mocroti antigen proteins is represented by SEQ ID NO:3 or SEQ ID NO:5. An immunoreactions spectrum of Babesia mocroti is acquired, the immunoreactions of recombinant proteins Bm2D33 and Bm2D36 with mouse serum after an acute stage are obviously decreased in the protein chip analysis of specific IgG antibody, and the recombinant proteins Bm2D33 and Bm2D36 can be used for detecting disease transformation progress of Babesia mocroti from the acute stage to a chronic stage. The recombinant proteins Bm2D33and Bm2D36 present very high specificity, namely 100% in the cross reaction tests of the serum of patients with falciparum malaria.

The invention discloses a preparation method of a controlled-release capsule with functions of detoxifying and diarrhea stopping. The controlled-release capsule is prepared from scabrid smallhooked hedyotis herb and auxiliary materials. According to the property of the scabrid smallhooked hedyotis herb, an extraction technology is optimized. Furthermore, aiming at the problem that the existing form bioavailability is low, one part of the scabrid smallhooked hedyotis herb is prepared into a quick-release pellet, the other part of the scabrid smallhooked hedyotis herb is prepared into a controlled-release pellet, and the two pellets are filled to prepare the capsule, so that the controlled-release capsule can be taken by patients in both of the acute stage and the chronic stage of colitis gravis, and therefore, the effect of treating both symptoms and root causes can be achieved, and the recurrence of the colitis gravis can be more effectively cured.

The invention discloses a western medicinal compound for treating idiopathic pulmonary fibrosis and applications of the western medicinal compound. The western medicinal compound is prepared by mixing piperazine adipate and prenylamine, wherein the mass ratio of piperazine adipate to prenylamine is (8-12):1. When the western medicinal compound is used for treating idiopathic pulmonary fibrosis, the administration dosage for adults is 1.8-2.0 mg / kg / day. The western medicinal compound has good treatment effects for idiopathic pulmonary fibrosis at all stages including the acute stage, subacute stage, chronic stage and acute attack stage of chronic idiopathic pulmonary fibrosis, the clinical experiment proves that the total effective rate of the western medicinal compound for idiopathic pulmonary fibrosis is 90.0-97.5 %, the relapse seldom occurs after the idiopathic pulmonary fibrosis is completely treated, no toxic and side effects exist, and the western medicinal compound has the wide application value.

The invention relates to the technical field of traditional Chinese medicine. The purpose of the invention is to provide a traditional Chinese medicine composition for improving the chronic phase of diabetes according to the understanding mechanism of traditional Chinese medicine on the chronic phase of diabetes, which is composed of the following raw materials by weight: reed root 10-20 parts, 10-20 parts of Ophiopogon japonicus, 6-10 parts of Polygonatum polygonatum, 15-25 parts of Chinese yam, one pair per day, 3 days as a course of treatment, the raw materials of the traditional Chinese medicine composition provided by the invention are easy to get, and the curative effect is good. It has no side effects, and has been taken by more than hundreds of patients with chronic diabetes, and the effective rate is over 96% according to statistics.

A method to treat the chronic stage of heart injury after ischemia or reperfusion by administering Midkine to a subject in need of such treatment is described.

The invention relates to a traditional Chinese medicine formula for treating chronic-stage anus eczema. The traditional Chinese medicine formula is composed of radix sophorae flavescentis, dried alum, belvedere fruit, firewood, wild chrysanthemum flower, indigo, angelica, herba schizonepetae, xanthium and calamus. The formula has the characteristics of tonifying the blood and promoting blood circulation, removing wind and promoting tissue regeneration, disinfecting and relieving itching and the like.

Blood brain barrier (BBB) permeabilizers, such as mannitol, can facilitate the entry of stem cells from the periphery to the stroke brain. It is unknown whether BBB permeation in the chronic stage of the disease still facilitates the entry of stem cells from the periphery to the injured brain. Evidence herein shows BBB permeation in the chronic stage of stroke assisted in the entry of stem cells from the periphery to the stroke brain. Stroke models treated with human umbilical cord stem cells (hUCBC) only (2 million viable cells), mannitol or a combination. Results revealed that hUCBC alone or combined with mannitol displayed significant behavioral and histological deficits compared to control animals, with the HUCBC-mannitol combined treatment showing improvements over hUCBC only treatments in brain cell survival in the peri-infarct area. BBB permeation in chronic stroke also lowers the effective stem cell dose necessary to improve functional outcomes.

The peptidoglycan layer is a vital component of the bacterial cell wall, which comprises 4→3 and 3→3 transpeptide cross-linkages, the formation of which are catalyzed by D,D- and L,D-transpeptidases, respectively. Methods for the treatment of bacterial infections with agents that inhibit L,D-transpeptidases, either alone or in combination with D,D-transpeptidase inhibitors, are provided herein. Also provided are methods for the treatment of chronic stage tuberculosis with agents that inhibit enzyme with L,D-transpeptidase activity.

The present invention relates to a method for treating a patient having suffered from severe aphasia associated with cerebrovascular accident chronic stage for at least three years, wherein said treatment consists essentially of administering a composition comprising 2-oxo-1-pyrrolidineacetamide as an active ingredient and a pharmaceutically acceptable carrier.

An orally taken Chinese medicine for treating viral myocarditis is prepared from 5-7 Chinese-medicinal materials including American ginseng, gypsum, arnebia root, borneol, etc. Two prescriptions for different stages are disclosed.

The compound Chinese onion preparation for treating chronic obstructive lung disease is prepared with Chinese onion, trichosanthes peel, Chinese goldthread, immature bitter orange, cassia twig and other chinese medicine materials. The preparation process includes crushing material, ethanol extraction, depression recovery of ethanol, concentration, adding supplementary material, vacuum drying to obtain dry extract, crushing, and further steps to prepare tablet, capsule, drip pills and micro pills. The compound Chinese onion preparation has obvious functions of relieving cough, eliminating phlegm and relieving asthma, and may be used to treat chronic obstructive lung disease effectively. It is ideal medicine for COPD in acute stage and COPD in prolonged stage and chronic stage.

The invention particularly relates to a compound pumpkin vine ointment and a preparation method thereof. Every 1000 parts by weight of ointment comprises the following active pharmaceutical ingredients in parts by weight: 51.73-71.73 parts of pumpkin vine (carbonized), 39.38-49.38 parts of mirabilite, 2.35-22.35 parts of Chinaberry seed (carbonized), 10.58-30.58 parts of phenol, 155.76-255.76 parts of flour, and the balance of water and caramel. The preparation method comprises the following steps: adding mirabilite into a certain amount of water, heating to dissolve the mirabilite, filtering, and collecting the filtrate; adding pumpkin vine (carbonized) and Chinaberry seed (carbonized) which are pulverized into fine powder and screened, evenly mixing, adding a right amount of caramel, evenly mixing, and adding flour while evenly stirring; and finally, adding phenol, and evenly mixing to obtain the compound pumpkin vine ointment. The compound pumpkin vine ointment has comprehensive and unique effects on diminishing inflammations, removing toxicity, promoting the subsidence of swelling, alleviating pain, evacuating pus, promoting blood circulation and dredging collaterals for ulcerand furuncle, and can be effectively used in acute and chronic stages of ulcer as well as early, medium and later stages of ulcer. The compound pumpkin vine ointment can quickly take effect, and is not irritating to skin.

The invention discloses a Chinese medicinal formula for treating chronic anal eczema, which is prepared from complete Chinese angelica, white peony root, Szechuan lovage rhizome, medicinal cyathula root, salvia, licorice root, common burreed rhizome, zedoary, divaricate saposhnikovia root, wild chrysanthemum, cutch, paniculate swallowwort root and dried alum. The Chinese medicaments are decocted for fumigation by using water, the decoction is used for one dose every day and once in the morning and the evening, and a treatment course contains continuous 10 days. The formula has the effects of clearing away heat and toxic material, dispelling wind and dissipating stagnation, eliminating putridity and engendering flesh, is simple and effective, can quickly heal the wound, and achieves the effect of healing.

The invention relates to an ashi acupuncture point self-detection health-protection massage tool for low back pain. The tool disclosed by the invention comprises a first handheld rod 1, a second handheld rod 2, a first base plate 3, a second base plate 4 and pressing sleeve pieces 5, and is characterized in that the first handheld rod 1 is connected with the first base plate 3 through a first hinge 7; the second handheld rod 2 is connected with the second base plate 4 through a second hinge 10; the first handheld rod 1 and the second handheld rod 2 are respectively provided with a plurality of insertion holes; the pressing sleeve pieces 5 are provided with insertion rods According to the ashi acupuncture point self-detection health-protection massage tool for the low back pain, a patient can conveniently determine the position of an ashi acupuncture point under a certain force metering state and execute pertinent intervention on the acute stage and the chronic stage of the low back pain through different sleeve pieces; the tool is simple in structure and convenient to carry, is a measure for active intervention for a low back pain patient in an absolute bed rest stage, and can be used for daily waist ache health protection.

The invention discloses application of a recombination human fibroblast growth factor-21 (rhbFGF21) in preparation of a medicament for preventing and treating ischemic arrhythmia. The study of the invention finds that preventive administration of the rhbFGF21 is performed on a myocardial infarction animal model before myocardial infarction, so that the occurrence rate of acute-stage arrhythmia after myocardial infarction can be obviously reduced; preventive administration of the rhbFGF21 is performed on the infarction animal model before myocardial infarction, and one-week continuous intraperitoneal injection administration of the rhbFGF21 is performed on the infarction animal model after myocardial infarction, so that the occurrence rate of chronic-stage arrhythmia after myocardial infarction can be obviously reduced; preventive administration of the rhbFGF21 is performed on the infarction animal model before myocardial infarction and one-week continuous intraperitoneal injection administration of the rhbFGF21 is performed on the infarction animal model after myocardial infarction, and complications of myocardial fibrosis and heart failure after myocardial infarction can be obviously prevented. The invention provides a safe and effective treatment method and medicament for preventing and treating ischemic arrhythmia, and also provides a convincing theoretical basis for the rhbFGF21 serving as a medicament for preventing and treating ischemic arrhythmia.

The invention provides an application of a sulfoxide compound in the treatment of inflammatory bowel diseases. The sulfoxide compound has a structure represented by general formula (I) shown in the description. The sulfoxide compound has treatment effects on acute ulcerative colitis mice, chronic ulcerative colitis mice and Crohn's disease mice, and can be applied to drugs for treating or preventing the inflammatory bowel diseases.

The present invention discloses the application of kidney reinforcing and rheumatism treating bolus in treating gout in chronic period. The kidney reinforcing and rheumatism treating bolus is prepared with angelica, ground beetle, white stiff silkworm, honeycomb, black tail snake and other Chinese medicine materials. It has obvious curative effect on gout in chronic period, and when it is taken together with available gout treating medicine granule, even high curative effect will be resulted in.